Mark Erlander, Cardiff Oncology CEO

Cardiff teas­es on­va­nsert­ib ef­fi­ca­cy in col­orec­tal can­cer ahead of first-line read­out

Cardiff On­col­o­gy’s PLK1 in­hibitor showed hints of ef­fi­ca­cy in a shelved Phase II test in sec­ond-line col­orec­tal can­cer, boost­ing Cardiff’s share price ahead of an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.